Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)

A Double Blind, Randomized, Placebo Controlled Study to Evaluate Efficacy and Safety of "VIRACIDE" in the Management of Corona Virus Disease 2019 (COVID-19)

This is a double blind randomized placebo controlled study will be conducted on 124 subjects, 50 years and older with mild or asymptomatic COVID-19. If symptomatic, symptoms are mild (cough, weakness, sore throat, low grade fever 38.50С, respiratory rate should not be more than 22 / min, resting SpO2 >95%, normal highly sensitive C-reactive protein (HS-CRP) (<10mg/L). There are no signs of dehydration, sepsis or shortness of breath.

The study will be conducted at two centers. There will be a screening visit at Day -4 followed by three visits at the center at Days 1, 7 and 15 and a follow-up visit on Day 28. All participants will be randomized to receive either ViraCide (investigational product) or matching placebo. All subjects will receive SOC therapy.

Note: If subject is discharged before Day 15 PI's discretion as per patients health condition, then assessments scheduled for Day 15 will be carried out on the discharge day (as far as possible and those not performed will be noted on appropriate CRF page) and Day 15 visit will be done telephonically.

Study Overview

• Status: Completed
• Conditions: Covid19
• Intervention / Treatment: Dietary supplement: Investigational Product - ViraCide; Other: Placebo - Starch Powder Soft gels

Detailed Description

Day 1 Randomization, Vital Signs, Pulse oximetry, AE/SAE, Concomitant Medication, ViraCide/ Placebo treatment start, NEWS scoring; 7-point ordinal scoring Day 7 Physical Examination, Vital Signs, AE/SAE, Concomitant Medication, ViraCide/ Placebo Compliance check, Pulse oximetry; NEWS scoring; 7-point ordinal scoring.

(Note: If the subject is discharged on this day as per PI's discretion and patient's health condition then assessment scheduled for day 15 will be carried out on discharge day).

Day 15 Physical Examination, Vital Signs, AE/SAE, Concomitant Medication, ViraCide/ Placebo treatment end, RT-PCR for Sars- Co-V2, Hs-CRP, Safety Lab Tests, Pulse oximetry; NEWS scoring; 7-point ordinal scoring, ViraCide/ Placebo Compliance check, Lab assessment including urine analysis Day 28

Phone call follow up for time :

• until negative RT-PCR for Sars-Co- V2, COVID-19 related mortality,
• development of any COVID-19 symptom,
• development of any worsening of comorbid condition;
• Development of new AE/SAE; Resolution status of previous AE/SAEs

Note: If subject is discharged before Day 15on PI's discretion as per patients health condition, then assessments scheduled for Day 15 will be carried out on the discharge day (as far as possible and those not performed will be noted on appropriate CRF page) and Day 15 visit will be done telephonically.

• Study Type: Interventional
• Enrollment (Actual): 118
• Phase: Not Applicable

Contacts and Locations

Study Locations

• India
  • Andhra Pradesh
    • Srikakulam, Andhra Pradesh, India, 532001
      • Department of General medicine/ clinical research. Government medical college and Government general hospital
  • Maharashtra
    • Pune, Maharashtra, India, 411019
      • Gunjkar Multispeciality Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. 50 years or older
2. Both male and female subjects will be included

3. Positive oropharyngeal/nasal swab RT-PCR for Sars-Co- V2. Diagnosed not more than 2 days ago(diagnosis

   ≤2days).

4. Either asymptomatic or have mild symptoms. Onset of symptoms within no more than 4 days If symptomatic, symptoms are mild (cough, weakness, sore throat, low grade fever 38.50С, respiratory rate should not be more than 22 / min, resting SpO2 >95%, normal highly sensitive C-reactive protein (HS-CRP) (<10mg/L). There are no signs of dehydration, sepsis or shortness of breath.
5. Chronic stable medical conditions: diabetes mellitus, or hypertension, or chronic heart disease. Under treatment and controlled by medication
6. Signed informed consent/or consent given through text message, WhatsApp ore-mail.
7. Ability to understand the requirements of the Research Protocol and follow the research procedures.
8. Subject should be willing to be managed in isolation wards
9. Negative pregnancy test (for female participants)
10. Adequate contraception for study duration

Exclusion Criteria:

1. Less than 50years
2. With severe COVID-19 symptoms requiring immediate hospitalization
3. Investigator considers the subject unsuitable for ViraCide
4. History of symptoms of more than 4days
5. COVID-19 diagnosed >2 days ago using oropharyngeal/nasal swab RT-PCR forSars-Co-V2
6. History of cardiopulmonary resuscitation
7. Subjects having history of organ failure or conditions requiring ICU monitoring and treatment, such as severe liver disease, severe renal dysfunction, upper gastrointestinal hemorrhage, disseminated intravascular coagulation or any other condition that in the PI"s opinion makes the subject unfit to participate
8. Respiratory failure, ARDS or need of mechanical ventilation
9. History of acute exacerbation of comorbidity like heart failure, diabetic ketoacidosis, myocardial infection, major cardiac rhythm disorder or any other condition that in the PI"s opinion makes the subject unfit to participate
10. History of or current hepatic failure or severely compromised liver function, or renal failure or having chronic kidney disease or acute renal failure
11. History of or currently receiving treatment for an endocrine disorder like hypothyroidism, hyperthyroidism that is likely to affect the basal heart rate.
12. History of or currently under treatment for asthma [exception: patients with history of asthma, not on medications/inhalers/nebulizers for at least 6 months before study start), COPD, bronchiectasis, asbestosis and other such chronic lung conditions that can compromise SpO2 and RR.
13. HIV, HBsAg, HCV positive
14. Any condition causing immunodeficiency
15. Systemic connective tissue disease or any autoimmune disease that is likely to affect HS-CRP levels
16. History of epilepsy/epileptic fit/convulsions in last 6 months or currently on treatment for it
17. History of or currently having malignancy and being treated for it. (exception: histologically confirmed and cured carcinoma in situ)
18. Hypersensitivity reaction to Study drug/placebo
19. Any psychiatric issue for which the subject is currently undergoing treatment
20. Any history of drug/alcohol dependence within 30 days of screening or current drug/alcohol dependence
21. Inability to understand the requirements of the Research Protocol and follow the research procedures.
22. Pregnant or lactating;
23. Not willing to use adequate contraception during study duration
24. Participation in any other clinical study less than 3months before the start of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Investigational product; Experimental, Investigational Product Ingredient : ViraCide Dosage form softgels . Fequency: 3 soft gels, two times every day after breakfast and dinner . Duration: 14 days+ SOC Therapy	Dietary supplement: Investigational Product - ViraCide; Viracide; Other Names: Investigational Product
Placebo Comparator: Placebo; Ingredient, Placebo Ingredient Starch softgels. Frequency: 3 soft gels, two times everyday after breakfast and dinner . Duration:14 days + SOC Therapy	Other: Placebo - Starch Powder Soft gels; Starch Powder Soft gels; Other Names: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0	The proportion of cases with National Early Warning Score reduction from 3 to 0 till discharge day between two groups. This score is associated with clinical risk and a decrease in score indicates a decrease in the risk to the patient and improvement in clinical condition.	First treatment date up to discharge day, an average of 1 week
Number of Participants With 7-point Ordinal Scale Score Change From 3 to 1	Proportion of cases with 7-point ordinal scale score reduction from 3 to 1 till day 7. This score is associated with clinical improvement and a decrease in score indicates improvement in patient's clinical condition.	First treatment date up to day 7, i.e. up to 1 week
Time to a Negative COVID-19 Nucleic Acid Testing	Time to COVID-19 nucleic acid testing negativity in oropharyngeal/nasal swab)	Time Frame: First treatment date up to 28 days
Rate of Progression on National Early Warning Score	Rate of progression to the severe/critical COVID-19 disease	First treatment date up tp 28 days (28 days)
Rate of Progression on 7- Point Ordinal Scale	Rate of progression to the severe/critical COVID-19 disease	First treatment date up to 28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ICU Admissions	Incidence of ICU admissions	Time frame: 28 days
Subject Survival	Subject survival in the trial	28 days
Incidence of Mechanical Ventilation	Number of incidences of mechanical ventilation due to COVID-19 infection	28 days
Change in Clinical or Laboratory Assessment of Comorbid Condition	To evaluate any decline in health condition due to comorbidity	28 days
Percent of Participants With Worsening Comorbid Condition	Percent of participants with worsening comorbid condition.	28 days

Collaborators and Investigators

• Sponsor: The Herb, Inc
• Collaborators: ProRelix Services LLP
• Investigators: Principal Investigator: Dr.Ninad Naik, MD(Ayurveda), Gunjkar Multispeciality Hospital; Principal Investigator: Dr. A Gopal Rao, MD(Med), Government Medical College and Government General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 16, 2020
• Primary Completion (Actual): December 12, 2020
• Study Completion (Actual): December 12, 2020

Study Registration Dates

• First Submitted: October 19, 2020
• First Submitted That Met QC Criteria: October 20, 2020
• First Posted (Actual): October 22, 2020

Study Record Updates

• Last Update Posted (Actual): August 12, 2021
• Last Update Submitted That Met QC Criteria: August 11, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Keywords: Coronavirus, (SARS-CoV-2)
• Additional Relevant MeSH Terms: Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Coronavirus Infections; Virus Diseases
• Other Study ID Numbers: NS-VC-CT01-20

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No